445 related articles for article (PubMed ID: 19217900)
1. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
[TBL] [Abstract][Full Text] [Related]
2. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2008 Nov; 597(1-3):27-33. PubMed ID: 18831971
[TBL] [Abstract][Full Text] [Related]
3. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2011 Oct; 668(3):355-65. PubMed ID: 21816144
[TBL] [Abstract][Full Text] [Related]
4. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
Tadori Y; Kitagawa H; Forbes RA; McQuade RD; Stark A; Kikuchi T
Eur J Pharmacol; 2007 Nov; 574(2-3):103-11. PubMed ID: 17692841
[TBL] [Abstract][Full Text] [Related]
5. Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2011 Sep; 666(1-3):43-52. PubMed ID: 21658377
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y; Kikuchi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
Heusler P; Newman-Tancredi A; Loock T; Cussac D
Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
[TBL] [Abstract][Full Text] [Related]
8. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
Tadori Y; Miwa T; Tottori K; Burris KD; Stark A; Mori T; Kikuchi T
Eur J Pharmacol; 2005 May; 515(1-3):10-9. PubMed ID: 15894311
[TBL] [Abstract][Full Text] [Related]
10. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
11. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
Bruins Slot LA; De Vries L; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2006 Mar; 534(1-3):63-70. PubMed ID: 16497294
[TBL] [Abstract][Full Text] [Related]
12. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
[TBL] [Abstract][Full Text] [Related]
13. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976
[TBL] [Abstract][Full Text] [Related]
14. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
[TBL] [Abstract][Full Text] [Related]
15. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
Novi F; Millan MJ; Corsini GU; Maggio R
J Neurochem; 2007 Aug; 102(4):1410-24. PubMed ID: 17532788
[TBL] [Abstract][Full Text] [Related]
16. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
18. Hyperprolactinemia with aripiprazole: understanding the paradox.
Saraf G; Behere RV; Venkatasubramanian G; Rao NP; Varambally S; Gangadhar BN
Am J Ther; 2014; 21(3):e80-1. PubMed ID: 22357167
[TBL] [Abstract][Full Text] [Related]
19. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Etievant A; Bétry C; Arnt J; Haddjeri N
Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
[TBL] [Abstract][Full Text] [Related]
20. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation.
Bruins Slot LA; Palmier C; Tardif S; Cussac D
Neuropharmacology; 2007 Aug; 53(2):232-41. PubMed ID: 17588617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
